Northwire Canada EditionSunday, July 12, 2026
Sign inSubscribe
Northwire
⌕
GLDN 0.055 +0.0% BRON 0.040 +0.0% BTO 5.43 −0.7% ESK 0.365 −2.7% AUMN 0.275 +0.0% GGX 0.040 +0.0% S 0.155 +29.2% NNX 0.035 +0.0% ABX 51.90 −0.6% TTS 2.40 −4.0% FCI 0.400 −9.1% GR 0.075 +0.0% AII 23.38 +12.4% TUNG 1.72 +1.8% LGO 1.01 −2.9% EMM 0.080 +0.0% GLDN 0.055 +0.0% BRON 0.040 +0.0% BTO 5.43 −0.7% ESK 0.365 −2.7% AUMN 0.275 +0.0% GGX 0.040 +0.0% S 0.155 +29.2% NNX 0.035 +0.0% ABX 51.90 −0.6% TTS 2.40 −4.0% FCI 0.400 −9.1% GR 0.075 +0.0% AII 23.38 +12.4% TUNG 1.72 +1.8% LGO 1.01 −2.9% EMM 0.080 +0.0%
Earnings Routine −

Microbix Reports Results for H1 & Q2 2026

Microbix Revenue Plunges on China Sales Collapse; Cash Burn Concerns Mount Despite Q2 Stabilization

By The Northwire Desk — AI Analysis May 14, 2026 · 08:01 MBX · 0.255 MICROBIX BIOSYSTEMS INC. J
Executive Summary
  • Microbix Biosystems reported H1 and Q2 2026 financial results showing a significant decline in revenue compared to prior year periods.
  • Total Revenue for Q2 2026 was $3,377,708, down 37% from $5,324,864 in Q2 2025.
  • Antigen Revenues dropped 40% to $2,584,552, primarily driven by a $2 million reduction in sales to a Chinese distributor.
  • H1 2026 Total Revenue was $7,596,617, down 33% from $11,368,866 in H1 2025.
  • The company transitioned from profitability to an operating/net loss of $1.43 million in Q2 and $2.60 million in H1.
  • Gross Margin compressed significantly to 48% in Q2 (down from 60%) and 44% for H1 (down from 61%).
  • Cash used in operating activities was $307,771 in Q2 compared to cash provided of $994,052 in the prior year period.
  • Balance sheet as of March 31, 2026 shows Cash Balance of $8,130,795 with Total Liabilities of $10,224,946.
Material Impact
  • The revenue decline is consistent with the trend established in Q1 2026 and FY2025 results where the China distributor issue was already flagged.
  • While the specific cash burn rate improved in Q2 ($307k used vs $2.6M used in Q1), the gross margin compression indicates structural profitability issues that are not easily reversible without volume recovery.
  • The loss of the Chinese distributor revenue stream represents a permanent reduction in top-line capacity unless new clients replace it, which has not yet materialized to offset the decline.
  • The market likely anticipated this deterioration given the Q1 2026 disclosure regarding the C$2M reduction in sales; therefore, the news is negative but priced-in rather than a sudden shock.
  • The widening net loss ($2.60M H1 vs $877k profit H1 25) confirms the company is not on track to meet breakeven targets without significant operational changes or capital injection.
MBX · Price
Company Overview
  • Microbix Biosystems develops and manufactures life-science products including antigens, Quality Assessment Products (QAPs), and reference materials for molecular diagnostics.
  • Flagship Projects include the Kinlytic® urokinase drug program (partnered with Sequel Pharma) targeting market re-entry by 2028.
  • Core revenue drivers are Antigen sales (historically dependent on Chinese distributor) and QAPs products used in clinical laboratory proficiency testing.
  • The company holds ISO 9001/13485 accreditations, FDA registration, and operates in over 30 countries.
Read the original news release →

More from MICROBIX BIOSYSTEMS INC. J

Apr 27, 2026 · 07:00

Microbix Product Validation Fails to Offset Revenue Decline and Cash Burn Concerns

Other Apr 15, 2026 · 07:00

Microbix Biosystems Showcases HCV Mimetic as Revenue Contracts Shrink and Cash Burn Accelerates

Other Mar 17, 2026 · 07:00

Microbix Presents Reference-Material Innovations at EUROGIN

Drill Results Mar 10, 2026 · 16:13

Microbix partner Sequel continues work on Kinlytic

Production / Operations Mar 10, 2026 · 07:00

Microbix's Clot-Buster Drug Project Advances

Production / Operations Feb 12, 2026 · 17:17

Microbix loses $1.16-million in fiscal Q1

Earnings